Study on Telisotuzumab Vedotin for Previously Treated c-Met+ Non-Small Cell Lung Cancer

Inclusion Criteria

• Have advanced or metastatic non-small cell lung cancer (NSCLC).
• Have NSCLC with a c-Met+ marker, confirmed by a specific lab test. Patients need to provide a tumor sample for this test.
• Have a type of NSCLC that is not squamous and does not have a specific mutation in the EGFR gene. Patients with other mutations can participate if they meet all other criteria.
• Have received no more than two previous treatments for advanced cancer, including one chemotherapy treatment.
• Have tried and not responded to chemotherapy and an immune checkpoint inhibitor, or are not eligible for these treatments.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have had any brain metastases treated and stable before starting the study.

Exclusion Criteria

• Have had radiation therapy to the lungs within six months before starting the study.
• Have received a live vaccine within 30 days before starting the study.
• Have a type of lung cancer called adenosquamous.
• Have a history of other cancers, except those specified in the study.
• Have a history of lung diseases like interstitial lung disease or pneumonitis that required steroid treatment.
• Have signs of lung fibrosis or recent lung inflammation, unless deemed insignificant by a doctor.
• Have unresolved side effects from previous cancer treatments, except for hair loss or mild anemia.
• Have had major surgery within 21 days before starting the study.
• For participants in France and Czech Republic: Must not have active HIV, hepatitis B, or hepatitis C infections, or uncontrolled autoimmune diseases.